<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745235</url>
  </required_header>
  <id_info>
    <org_study_id>Chauvet-Gelinier UNAFAM 2017</org_study_id>
    <nct_id>NCT03745235</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Influence of a Mindfulness-based Stress Reduction Program vs. Routine Management on Psychological Variables and Biological Markers Related to Immuno-inflammation Associated With Psychological Stress in Caregivers of Patients With Severe Psychiatric Disorders</brief_title>
  <acronym>MindInfCare</acronym>
  <official_title>A Randomized Controlled Study Comparing the Influence of a Mindfulness-based Stress Reduction Program vs. Routine Management on Psychological Variables and Biological Markers Related to Immuno-inflammation Associated With Psychological Stress in Caregivers of Patients With Severe Psychiatric Disorders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project is to study the influence of mindfulness meditation on
      psychological health (stress level, affects, emotions) and physical health parameters (rate
      of inflammatory markers in the blood, activity of white blood cells involved in
      immuno-inflammation) in caregivers of people with psychiatric disorders. This study will
      provide the objective scientific data required for the development of mindfulness meditation
      programs for psychiatric caregivers.

      80 participants will be randomly assigned to one of the following two groups:

        -  40 participants in the &quot;Mindfulness&quot; group who will attend mindfulness meditation
           sessions in addition to their standard follow-up

        -  40 participants in the &quot;Control&quot; group who will have a standard follow-up The duration
           of participation is 12 months and includes 3 visits and 8 mindfulness-based meditation
           sessions for the &quot;Mindfulness&quot; group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of inflammation by analysis of US-CRP blood levels</measure>
    <time_frame>Change from Baseline US-CRP blood levels at 3 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of inflammation by analysis of IL-6 blood levels</measure>
    <time_frame>Change from Baseline IL-6 blood levels at 3 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of lymphocyte activity Th1 Th2 Th17 Treg</measure>
    <time_frame>Change from Baseline lymphocytes activity Th1 Th2 Th17 Treg at 3 and 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Psychiatry</condition>
  <condition>Caregivers</condition>
  <condition>Mindfulness</condition>
  <arm_group>
    <arm_group_label>&quot;Mindfulness&quot; group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment as Usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stress reduction program based on mindfulness</intervention_name>
    <description>a two and a half hour session per week for 8 weeks</description>
    <arm_group_label>&quot;Mindfulness&quot; group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>venipunctures</intervention_name>
    <description>1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months</description>
    <arm_group_label>&quot;Mindfulness&quot; group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>psychometric questionnaires</intervention_name>
    <description>Cohen PSS' perceived stress scale
Beck's anxiety and depression questionnaires
Watson's affectivity questionnaire, positive affect and negative affect schedule
optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver
IN-OUT DASQ dispositional affective style questionnaire</description>
    <arm_group_label>&quot;Mindfulness&quot; group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient who has given oral consent

          -  adult patient

          -  a caregiver of a person with a severe psychiatric disorder (schizophrenia, recurrent
             depression, bipolar disorder, obsessive-compulsive disorder)

        Exclusion Criteria:

          -  protected adult

          -  patient not affiliated to the national health insurance system

          -  pregnant, parturient or breastfeeding woman

          -  person suffering from a severe psychiatric disorder indicating a state of
             decompensated stress (with risk of associated biological inflammatory disturbances)

          -  person suffering from an inflammatory disease (autoimmune, infectious, neoplastic,
             cardio-vascular pathologies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Christophe CHAUVET-GELINIER</last_name>
    <phone>+33 3 80 29 37 69</phone>
    <email>jean-christophe.chauvet-gelinier@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe CHAUVET-GELINIER, MD</last_name>
      <phone>+33 3 80 29 37 69</phone>
      <email>jean-christophe.chauvet-gelinier@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emmanuel HAFFEN, MD</last_name>
      <phone>+33 3 81 21 81 54</phone>
      <email>emmanuel.haffen@univ-fcomte.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

